Author

Dean Anthony Lee

Nationwide Children's HospitalORCID 0000-0001-6693-5392Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Alexia K. MartiniD· 1 shared Ali A. AshkariD· 1 shared Amy C. GrossiD· 1 shared Ana L. PortilloiD· 1 shared Andrea M. GlaspelliD· 1 shared Beau R. WebberiD· 1 shared Branden S. MoriarityiD· 1 shared Chun‐Yu CheniD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Alexia K. MartinORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintAug 30, 2025

Off-the-shelf allogeneic polyclonal CD38KO/CD38-CAR γδT cells for the treatment of T cell malignancies

Genesis Snyder, Alexia K. Martin, Yasemin Sezgin…·Meisam Naeimi Kararoudi

This paper develops CD38KO/CD38-CAR γδT cells for T cell malignancies, showing they effectively target T-ALL without causing fratricide or GvHD.

3 citations

humanproteomics

𝕏 PostBluesky

Cancer BiologyMolecular Therapy OncologyPeer-reviewedSep 26, 2024

Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma

Emily M. Ringwalt, Mark A. Currier, Andrea M. Glaspell…·Timothy P. Cripe

This study shows trabectedin enhances oncolytic virotherapy by reducing anti-viral barriers and boosting immune-mediated tumor regression in preclinical models.

9 citations

𝕏 PostBluesky